Nov 09, 2020 / 09:15PM GMT
Evan David Seigerman - Crédit Suisse AG - Research Division - VP & Senior Equity Research Analyst
And there we are. We're live, unceremoniously like that. Well, my name is Evan Seigerman. I'm the senior large-cap biopharma analyst here at Crédit Suisse. And it's my pleasure to introduce Amgen on the first day of our Virtual Healthcare Conference. I'm looking forward to next year when we can all be in person. We were reminiscing about how nice that was. But from Amgen, we have Peter Griffith, CFO; Murdo Gordon, Global Commercial Operations; and of course, Arvind Sood, VP of IR.
I was told very specifically to give it to Arvind after the introduction. So Arvind, take it away.
Arvind Sood - Amgen Inc. - VP of IR
Evan, thank you very much. Good afternoon, everybody. I really appreciate this opportunity. As you mentioned, Evan, we would much rather be at The Phoenician in Scottsdale, but that's kind of the way it is right now.
So Evan, let me just tee up some key topics, and then we can move on to your questions. Our
Amgen Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 10, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers